EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database

Boyi Liu iD, Wenchao Zhang, Ruizhe Huang iD, Dinwen Liu, Jiaxing Liu, Ao Han, Yike Li, Danna Chen

Cancer Medicine · 2026-04 · 15 (4)

DOI: 10.1002/cam4.71527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 30.03.2026. Verfasst von Boyi Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical College, Changsha Medical University, Changsha, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Adverse Drug Reaction Reporting Systems, Antineoplastic Combined Chemotherapy Protocols, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hunan Provincial Department of Education Fund Project, National Undergraduate Innovation and Entrepreneurship Training Program 2024 (Letter No. 13 [2024] from the Department of Higher Education), The "14th Five-Year Plan" Applied Characteristic Discipline of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Immune checkpoint inhibitors (ICIs) combined with platinum‐based compounds are commonly used in the treatment of certain malignant tumors. This study aims to analyze adverse events (AEs) associated with the combination therapy of ICIs and platinum‐based compounds by using the FAERS database.

Methods

This study retrieved relevant adverse event (AE) data from the FAERS database (2008–2024) and conducted a retrospective analysis of the collected AEs. Multiple disproportionality analysis algorithms were employed, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi‐item Gamma Poisson Shrinker (MGPS).

Results

Analysis of 28,585 reports identified 27 significant SOC‐level signals, strongest for hematological (ROR = 6.3), endocrine (ROR = 14.3), and hepatobiliary disorders (ROR = 4.49). Key PTs included malignant neoplasm progression (ROR = 16), febrile neutropenia (ROR = 15.31), and myocarditis (ROR = 16.3). 45.5% of AEs occurred within 1 month (median onset: 38 days). Combination therapy showed lower rates vs. monotherapy for malignancy progression and nephrotoxicity, but higher neurotoxicity (628 neuropathy cases).

Conclusion

The combination exhibits distinct early‐onset toxicities (early‐onset hematological/endocrine/hepatic) and novel risks (neuropathy/myocarditis/leukemia), necessitating enhanced initial monitoring and subgroup‐specific management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsAdverse Drug Reaction Reporting SystemsAntineoplastic Combined Chemotherapy ProtocolsNeoplasmsPlatinum CompoundsHumansUnited StatesUnited States Food and Drug AdministrationDatabases, FactualRetrospective StudiesBayes Theorem

Stichwörter der Autor:innen

FAERSdisproportionality analysisimmune checkpoint inhibitorsplatinum‐based agents

Substanzen

Immune Checkpoint InhibitorsPlatinum Compounds

Autor:innen und Institutionen

  • The First Clinical College, Changsha Medical University, Changsha, China.
  • Institute of Cytology and Genetics, Basic Medical School, University of South China, Hengyang, China.
  • Changsha Hospital for Maternal & Child Health Care, Changsha, China.
  • Department of Basic Medical Sciences, Changsha Medical University, Changsha, Hunan, China.
  • Hunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Changsha, China.

ORCID-Profile: Boyi Liu, Ruizhe Huang

Förderung

  • Hunan Provincial Department of Education Fund Project
  • National Undergraduate Innovation and Entrepreneurship Training Program 2024 (Letter No. 13 [2024] from the Department of Higher Education)
  • The "14th Five-Year Plan" Applied Characteristic Discipline of Hunan Province
  • Changsha Outstanding Youth Innovation Talent Development Program
  • The 2024 Hunan Provincial Student Innovation and Entrepreneurship Training Program Project, Xiang- jiaotong [2024] 191 - General Project - 5276
  • Natural Science Founda- tion of Hunan Province

Zitieren

APA

Liu, B., Zhang, W., Huang, R., Liu, D., Liu, J., Han, A., Li, Y., & Chen, D. (2026). A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71527

Vancouver

Liu B, Zhang W, Huang R, Liu D, Liu J, Han A, et al. A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71527

BibTeX
@article{Liu2026,
  author = {Liu, Boyi and Zhang, Wenchao and Huang, Ruizhe and Liu, Dinwen and Liu, Jiaxing and Han, Ao and Li, Yike and Chen, Danna},
  title = {A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cam4.71527}
}
Kostenlos starten →